Skip to main content
Premium Trial:

Request an Annual Quote

Miniature Mass Spec Firm 908 Devices Raises $7M

NEW YORK (GenomeWeb News) – Mass spectrometer firm 908 Devices has raised $7 million with an eye toward a total of $8 million in funding, according to a document filed with the US Securities and Exchange Commission on Tuesday by the Boston-based firm.

A 908 Devices spokesperson declined to identify the investors or say how proceeds would be used. In 2012, the company raised $8.1 million in a Series A round.

908 Devices was founded last year and is developing a hand-held mass spec that uses molecular traps "a thousand times smaller than those in conventional mass spectrometers," the company said on its website. It calls its technology High Pressure Mass Spectrometry, or HPMS.

While the initial market being targeted by the firm is the military and security sector, a company executive told GenomeWeb Daily News that HPMS is a "broad platform with a multibillion dollar market that includes life science," adding that among the markets that 908 Devices' technology could address are metabolomics and food safety testing.

The firm has developed an instrument that weighs about three pounds "and runs for extended periods from a lithium-ion battery." That compares to "today's best field portable … mass spectrometers that are fragile, large, and weigh upward of 35 pounds."

In April, 908 Devices and In-Q-Tel announced a partnership to develop new mass spec analyzers. The technology is funded in part by the Department of Homeland Security Science and Technology Directorate, an IQT customer agency.

The Scan

WHO Seeks Booster Pause

According to CNN, the World Health Organization is calling for a moratorium on administering SARS-CoV-2 vaccine boosters until more of the world has received initial doses.

For Those Long Legs

With its genome sequence and subsequent RNAi analyses, researchers have examined the genes that give long legs to daddy longlegs, New Scientist says.

September Plans

The New York Times reports that the US Food and Drug Administration is aiming for early September for full approval of the Pfizer-BioNTech SARS-CoV-2 vaccine.

Nucleic Acids Research Papers on Targeting DNA Damage Response, TSMiner, VarSAn

In Nucleic Acids Research this week: genetic changes affecting DNA damage response inhibitor response, "time-series miner" approach, and more.